Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4350 Cytoendoscopy for determining the depth of invasion and metastasis of rectal neuroendocrine tumours

Introduction: Rectal neuroendocrine tumours (rNETs) are relatively common submucosal tumours, but even low-grade rNETs can metastasise. The significance of endocytology (EC) in the clinical evaluation of rNETs has not been reported.

Conference:

Presenting Author: Tang Q

Authors: Bai J, Tian Y, Tang Q,

Keywords: rectal neuroendocrine tumour, cytoendoscopy, invasion, metastasis, tumour grade,

#3918 Efficiency of GemCap + mitotane in platinum and mitotane resistant adrenocortical carcinoma

Introduction: Gemcitabine, metronomic capecitabine and mitotane (M) combination (GemCap + M) is the most investigated and widely used regimen in 2nd and subsequent lines therapy of advanced adrenocortical cancer (ACC). In the largest retrospective study (N=145) only 28% of patients (pts) reached therapeutic concentration of mitotane (M), which translated into a significant improvement in the median progression free survival (PFS).

Conference:

Presenting Author: Zhulikov Y

Authors: Zhulikov Y, Kovalenko E, Bokhyan V, Evdokimova E, Khoroshilov M,

Keywords: adrenocortical cancer, gemcitabine, capecitabine, GemCap, mitotane,

#3659 The characteristics of somatostatin receptor PET/CT in bone metastases of neuroendocrine tumors

Introduction: Bone metastasis is a poor prognostic predictor of neuroendocrine neoplasms.

Conference:

Presenting Author: Xu J

Authors: Xu J, Xu X, Song S, Chen J,

Keywords: Bone metastasis of neuroendocrine neoplasms, 68Ga-DOTATATE, 68Ga-DOTANOC, PET/CT,

#3495 PFS evaluation in patients with advanced, non-resectable, progressive GEP-NET treated using combine radioligand/PRRT and CAPTEM therapy

Introduction: Prospective, single-arm, open-label, case series study with assessment the efficacy and safety of combined radioligand therapy (RLT/PRRT) and CAPTEM in advanced, non-resectable progressive GEP-NET (NCT04194125).

Conference:

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Nowicka G, Pałucki J,

Keywords: neuroendocrine tumor, combine therapy PRRT and CAPTEM, PFS,

#3284 Value of CgA and NSE as predictors of tumor response after combined PRRT and CAPTEM therapy in patients with progressive, advanced GEP-NET

Introduction: Combine PRRT and CAPTEM is a new approach in therapy of NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Nowicka G, Włodarczyk M, Nowicki M,

Keywords: CgA, NSE, neuroendocrine tumor, PRRT and CAPTEM,